C1q binding substances in pemphigus and bullous pemphigoid. Detection with a [131I] C1q binding assay.
A modification of the [125I]C1q binding assay was developed to allow the estimation of C1q binding activity (C1q BA) in pemphigus and bullous pemphigoid sera. The modifications include lower final concentration of PEG 6000 (1-5%) which permitted the use of sera that had been stored at -20 degrees C for extended periods of time; use of 131I instead of 125I and an [131I] C1q concentration of 5 microng/ml rather than 1 microng/ml. EDTA was used at a final concentration of 0-13 M to obviate the need for heat inactivation of sera. Sera from seventy-one patients with pemphigus and from 142 patients with bullous pemphigoid were tested for C1q BA. Of these 40% of the pemphigus and 20% of the bullous pemphigoid patients showed elevated C1q BA. A relationship between elevated C1q BA in serum and active disease was noted. Sequential samples from forty patients with pemphigus and thirty-seven patients with bullous pemphigoid demonstrated two different types of relationship between serum antibody titres to cutaneous antigens and C1a BA. In some patients serum antibody titres and C1q BA increased and decreased simultaneously; in others, increase of C1q BA followed increase of antibody titre and coincided with its decrease. The latter relationship supports the hypothesis that C1q BA may represent at least in part antigen-antibody complexes containing cutaneous antigens.
D000906:Antibodies / Q000032:analysis; D000936:Antigen-Antibody Complex; D003172:Complement C1; D003168:Complement Fixation Tests; D003165:Complement System Proteins; D004247:DNA; D006801:Humans; D010392:Pemphigus / Q000276:immunology*; D011092:Polyethylene Glycols; D012872:Skin Diseases, Vesiculobullous / Q000276:immunology*
D000906:Antibodies; D000936:Antigen-Antibody Complex; D003172:Complement C1; D011092:Polyethylene Glycols; D003165:Complement System Proteins; D004247:DNA